An older female client comes to the clinic for a regular check-up. The client tells the nurse that she has increased her daily doses of acetaminophen for the past month to control joint pain. Based on this patient's comment, which previous laboratory results should the nurse compare with today's laboratory report?

A. Accommodation: Mydriatic eye drops cause dilation of the pupils, but they do not directly affect the eye's ability to accommodate or focus on near objects. Therefore, accommodation may still be functional, though it can be affected indirectly due to the dilated pupils.
B. Pupillary constriction: Mydriatic eye drops are designed to dilate the pupils, so they inhibit or prevent pupillary constriction. This is the primary purpose of these drops, so pupillary constriction will not occur during their therapeutic effect.
C. Refraction: Refraction refers to the bending of light as it passes through the eye to focus on the retina. This function is generally maintained even when mydriatic drops are used, though changes in pupil size can affect the amount of light entering the eye.
D. Eye convergence: Convergence involves the inward movement of both eyes toward each other to maintain single binocular vision when focusing on a close object. While mydriatic drops primarily affect pupil dilation, convergence can still occur, though it may be affected by the degree of dilation.

A) Coronary artery disease: It is crucial to assess for a history of coronary artery disease (CAD) before administering sumatriptan, as the medication is a serotonin receptor agonist that can cause vasoconstriction of coronary arteries. This can increase the risk of serious cardiovascular events, such as heart attack or stroke, particularly in clients with preexisting CAD.

B) Seasonal allergic rhinitis: While seasonal allergic rhinitis may be a concern for other medications due to potential allergic reactions or interactions, it is not directly related to the administration of sumatriptan. This condition does not pose a significant risk with the use of sumatriptan.

C) Type 2 diabetes mellitus: Although type 2 diabetes mellitus is an important consideration in the overall health management of a client, it is not the most critical condition to assess before administering sumatriptan. However, if the client has diabetes with associated complications like cardiovascular disease, this would increase concern for using sumatriptan.

D) Irritable bowel syndrome: Irritable bowel syndrome (IBS) is a gastrointestinal disorder that typically does not influence the decision to administer sumatriptan. While IBS may affect a client’s comfort or medication regimen, it does not present the same immediate risks as coronary artery disease when using sumatriptan.